12:00 AM
 | 
Jan 05, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vidaza azacitidine regulatory update

The EC approved Vidaza azacitidine from Celgene to treat myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myelogenous...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >